Fertirelin Injection

Application scenario: Anovulatory infertility accounts for a significant proportion of female infertility, approximately 30%. Among them, patients with polycystic ovary syndrome (PCOS) are a high-risk group for anovulatory infertility. PCOS patients have multiple small follicles in their ovaries, but these follicles often fail to develop and mature properly, leading to infertility. Traditional therapeutic methods mainly rely on ovulation inducing drugs such as clomiphene. However, these drugs carry certain risks during use, which can easily lead to ovarian hyperstimulation syndrome (OHSS). OHSS is a serious iatrogenic complication, and patients may experience symptoms such as ovarian enlargement, ascites, and pleural effusion. In severe cases, it can even endanger their lives, posing a great threat to their physical health and safety.

Clinical value: A randomized controlled trial conducted on 200 PCOS patients fully demonstrated the significant effect in treating anovulatory infertility. The experimental results showed that after therapeutic with Flutilin, the ovulation rate of patients reached as high as 85%, and the pregnancy rate reached 40%, which was significantly higher than the clomiphene therapeutic group (ovulation rate of 65%, pregnancy rate of 25%). In addition, the therapeutic cycle is relatively short, usually only 5-10 days, which greatly reduces the physical and mental burden on patients during the therapeutic process and increases compliance. Many patients, after receiving therapeutic, not only successfully achieve ovulation and pregnancy, but also avoid the serious side effects that traditional drug therapeutic may bring, and their quality of life has been significantly improved.

Mechanism of action: The generation of male sperm is a complex and precise process that relies on the synergistic effect of follicle stimulating hormone (FSH) and testosterone. FSH is mainly secreted by the pituitary gland and can stimulate the seminiferous tubules of the testes, promoting sperm production and development. Testosterone is mainly secreted by testicular interstitial cells and plays an important role in sperm maturation and maintaining male sexual function. By stimulating the pituitary gland to secrete FSH and enhancing the function of testicular interstitial cells, sufficient hormone support is provided for sperm production, thereby promoting sperm production. At the same time, it can also regulate testosterone levels to maintain them within the normal range, improve male sexual function, and enhance the quality and vitality of sperm.

Clinical value: In the therapeutic of male infertility, the combination of testosterone supplementation therapy has demonstrated excellent therapeutic effects. Clinical studies have shown that after adopting this combination therapy, the patient's sperm count can significantly increase from<5 × 10 ⁶/mL to>20 × 10 ⁶/mL, providing more opportunities for conception. At the same time, the pregnancy rate of spouses has also increased to 35%, and many couples who were previously unable to conceive due to sperm deficiency have successfully welcomed their babies through this therapeutic plan. This program is particularly suitable for patients with hypogonadotropic hypogonadism (IHH), providing them with an effective therapeutic option and helping them achieve their reproductive dreams.

Application scenario: Endometriosis is a common disease among women of childbearing age, which can have many adverse effects on their physical health and quality of life. Patients usually experience symptoms such as dysmenorrhea, menstrual disorders, and in severe cases, infertility. Traditional therapeutic methods mainly rely on surgery or progesterone drugs, but surgery carries certain risks and has a high postoperative recurrence rate; Although progesterone drugs can alleviate symptoms, long-term use may bring significant side effects such as weight gain, emotional fluctuations, etc., affecting patients' physical health and quality of life.

Clinical value: A 6-month clinical trial evaluated the efficacy of Furirelin in the therapeutic of endometriosis. The experimental results showed that after therapeutic with fertirelin injection, the patient's dysmenorrhea score decreased by 60%, which means that the patient's pain symptoms were significantly relieved and their quality of life was significantly improved. At the same time, the menstrual disorder rate decreased from 75% to 20%, and the menstrual cycle gradually returned to normal. In addition, the natural pregnancy rate of patients has increased to 25%, and many patients who were previously infertile due to endometriosis have successfully become pregnant. More importantly, the drug has minimal impact on ovarian reserve function and will not affect the patient's future fertility, making it suitable for patients with fertility needs.

Application scenario: The estrogen level in premenopausal breast cancer patients is usually high, and the growth and proliferation of tumor cells often depend on the stimulation of estrogen. Traditional therapeutic methods mainly rely on oophorectomy or drug-induced castration. Although oophorectomy can rapidly reduce estrogen levels, it can cause irreversible physical damage to patients, affecting their fertility and endocrine balance; Although drug-induced castration is relatively non-invasive, it may also have significant side effects and unstable effects, which can have a serious impact on patients' physical health and quality of life.

Clinical value: A multicenter study involving 1000 premenopausal patients with breast cancer evaluated the therapeutic effect of futirelin combined with tamoxifen. The research results showed that after 5 years of therapeutic with Furirelin combined with Tamoxifen, the disease-free survival rate of patients reached 85%, and the overall survival rate reached 90%. This data was not significantly different from the surgical castration group, indicating that the combination therapy has a similar effect to surgical castration in inhibiting tumor recurrence and prolonging patient survival. In addition, the incidence of osteoporosis in the therapeutic group decreased by 40%, and cardiovascular events decreased by 25%. Osteoporosis and cardiovascular disease are important health problems faced by breast cancer patients in the long-term survival process. Use can effectively reduce the risk of these complications, improve the quality of life of patients, and provide guarantee for long-term health of patients.

Application scenario: The proliferation of prostate cancer cells is highly dependent on the stimulation of testosterone, and the higher the testosterone level, the faster the growth rate of tumor cells. Traditional therapeutic methods mainly rely on surgical castration or anti androgen drugs. Surgical castration can bring physical trauma and psychological pressure to patients, affecting their quality of life; Although anti androgen drugs can inhibit the effects of testosterone, long-term use may lead to drug resistance in tumor cells, and patients are prone to side effects such as hot flashes and decreased libido, affecting their physical and mental health.

Clinical value: In the therapeutic of advanced prostate cancer patients, the combination therapy of fertirelin injection and Bicalutamide has shown significant advantages. Clinical studies have shown that after adopting this combination therapy, patients' serum testosterone levels can be reduced to<50ng/dL, and tumor progression time can be prolonged to 18 months, which is significantly better than the monotherapy group (12 months). This means that combination therapy can more effectively control the growth and spread of tumors, prolonging the survival of patients. In addition, this plan can also reduce the occurrence of side effects such as hot flashes and decreased libido, improve the quality of life of patients, and enable them to maintain a good physical and mental state during the therapeutic process, and better cope with the disease.